bluebird bio Inc (NASDAQ:BLUE) – Equities researchers at William Blair issued their Q1 2019 earnings per share (EPS) estimates for shares of bluebird bio in a research note issued to investors on Friday. William Blair analyst R. Prasad forecasts that the biotechnology company will post earnings of ($2.31) per share for the quarter. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for bluebird bio’s Q2 2019 earnings at ($2.40) EPS.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.84). bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The business had revenue of $4.17 million during the quarter, compared to analyst estimates of $7.11 million. During the same quarter in the previous year, the firm posted ($1.88) earnings per share. The firm’s quarterly revenue was up 169.0% on a year-over-year basis.
A number of other equities research analysts also recently weighed in on BLUE. Maxim Group lifted their price target on shares of bluebird bio from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, November 30th. Canaccord Genuity started coverage on shares of bluebird bio in a research report on Tuesday, December 5th. They issued a “buy” rating and a $202.00 price target for the company. Cantor Fitzgerald set a $113.00 price target on shares of bluebird bio and gave the company an “underweight” rating in a research report on Monday, December 11th. Jefferies Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and lifted their price target for the company from $130.00 to $211.00 in a research report on Monday, December 11th. Finally, BMO Capital Markets set a $215.00 price target on shares of bluebird bio and gave the company a “buy” rating in a research report on Monday, December 11th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $192.35.
bluebird bio stock traded down $15.18 during midday trading on Monday, hitting $179.77. 1,020,655 shares of the stock were exchanged, compared to its average volume of 841,342. bluebird bio has a 52 week low of $74.45 and a 52 week high of $236.17. The firm has a market capitalization of $9,986.71, a P/E ratio of -23.32 and a beta of 2.06.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB bought a new stake in shares of bluebird bio during the fourth quarter worth $807,000. MetLife Investment Advisors LLC bought a new stake in shares of bluebird bio during the fourth quarter worth $3,935,000. Redmile Group LLC bought a new stake in shares of bluebird bio during the fourth quarter worth $46,270,000. Element Capital Management LLC bought a new stake in shares of bluebird bio during the fourth quarter worth $23,592,000. Finally, Kazazian Asset Management LLC grew its stake in shares of bluebird bio by 11.6% during the fourth quarter. Kazazian Asset Management LLC now owns 4,555 shares of the biotechnology company’s stock worth $811,000 after buying an additional 472 shares during the last quarter.
In other bluebird bio news, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the sale, the director now owns 7,000 shares of the company’s stock, valued at $1,500,660. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Nick Leschly sold 5,435 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $173.38, for a total transaction of $942,320.30. Following the sale, the chief executive officer now directly owns 171,009 shares in the company, valued at approximately $29,649,540.42. The disclosure for this sale can be found here. Insiders sold 70,598 shares of company stock worth $13,656,589 over the last three months. 3.90% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “bluebird bio Inc Forecasted to Post Q1 2019 Earnings of ($2.31) Per Share (BLUE)” was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/03/20/bluebird-bio-inc-forecasted-to-post-q1-2019-earnings-of-2-31-per-share-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.